You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
Extracellular vesicle-based vaccine platform displaying native viral envelope proteins elicits a robust anti-SARS-CoV-2 response in mice
Extracellular vesicle-based vaccine platform displaying native viral envelope proteins elicits a robust anti-SARS-CoV-2 response in mice
AbstractExtracellular vesicles (EVs) emerge as essential mediators of intercellular communication. DNA vaccines encoding antigens presented on EVs efficiently induce T-cell responses and EV-based vaccines containing the Spike (S) proteins of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) are highly immunogenic in mice. Thus, EVs may serve as vaccine platforms against emerging diseases, going beyond traditional strategies, with the antigen displayed identically to the original protein embedded in the viral membrane and presented as such to the immune system. Compared to their viral and pseudotyped counterparts, EV-based vaccines overcome many safety issues including pre-existing immunity against these vectors. Here, we applied our technology in natural EV’s engineering, to express the S proteins of SARS-CoV-2 embedded in the EVs, which mimic the virus with its fully native spikes. Immunizations with a two component CoVEVax vaccine, comprising DNA vector (DNAS-EV) primes, allowing in situ production of Spike harbouring EVs, and a boost using S-EVs produced in mammalian cells, trigger potent neutralizing and cellular responses in mice, in the absence of any adjuvants. CoVEVax would be the prototype of vaccines, where the sole exchange of the envelope proteins on EVs leads to the generation of new vaccine candidates against emerging viruses.
- Université Paris Diderot France
Microsoft Academic Graph classification: Extracellular vesicle Viral membrane Biology Virology Virus DNA vaccination Immune system Viral envelope Antigen Immunity
[SDV]Life Sciences [q-bio]
[SDV]Life Sciences [q-bio]
Microsoft Academic Graph classification: Extracellular vesicle Viral membrane Biology Virology Virus DNA vaccination Immune system Viral envelope Antigen Immunity
1. G. van Niel, G. D'Angelo, G. Raposo, Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 19, 213-228 (2018).
2. A. Dutta, Exosomes-based cell-free cancer therapy: a novel strategy for targeted therapy. Immunol Med. Sep 14:1-8 (2020).
3. J. D. Walker, C. L. Maier, J. S. Pober, Cytomegalovirus-infected human endothelial cells can 4. A. M. Booth, Y. Fang, J. K. Fallon, J. M. Yang, J. E. Hildreth, S. J. Gould, Exosomes and HIV 5. I. S. Zeelenberg, M. Ostrowski, S. Krumeich, A. Bobrie, C. Jancic, A. Boissonnas, A. Delcayre, J. B. Le Pecq, B. Combadière, S. Amigorena, C. Théry, Targeting tumor antigens to secreted 6. S. Kuate, J. Cinatl, H. W. Doerr, K. Uberla, Exosomal vaccines containing the S protein of the 8. F. Krammer, SARS-CoV-2 vaccines in development. Nature. 586, 516-527 (2020).
9. J. R. Mascola, S. W. Snyder, O. S. Weislow, S. M. Belay, R. B. Belshe, D. H. Schwartz, M.L. Clements, R. Dolin, B. S. Graham, G. J. Gorse, M. C. Keefer, M. J. McElrath, M. C. Walker, K. F. Wagner, J. G. McNeil, F. E. McCutchan, D. S. Burke, Immunization with envelope 10. S. E. Hensley, S. R. Das, A. L. Bailey, L. M. Schmidt, H. D. Hickman, A. Jayaraman, K.
11. R. M. Cardoso, M. B. Zwick, R. L. Stanfield, R. Kunert, J. M. Binley, H. Katinger, D. R.
16. S. Sridhar, S. Begom, A. Bermingham, K. Hoschler, W. Adamson, W. Carman, T. Bean, W.
17. X. Xu, X. Gao, Immunological responses against SARS-coronavirus infection in humans. Cell.
21. A. De Gassart, B. Trentin, M. Martin, A. Hocquellet, P. Bette-Bobillo, R. Mamoun, M. Vidal, 22. J. Pallesen, N. Wang, K. S. Corbett, D. Wrapp, R. N. Kirchdoerfer, H. L. Turner, C. A. Cottrell, Zhang, J. N. Ng, C. S. Cheng, J. Yu, L. Meng, R. F. Yang, S. T. Lai, Z. H. Guo, Y. Xie, W. F.
28. J. E. Park, K. Li, A. Barlan, A. R. Fehr, S. Perlman, P. B. McCray Jr, Gallagher T. Park, tropism. Proc. Natl. Acad. Sci. U. S. A. 113, 12262-12267 (2016).
29. M. Moulard, S. Hallenberger, W. Garten, H. D. Klenk, Processing and routage of HIV glycoproteins by furin to the cell surface. Virus Res. 60 (1) (1999). Preliminary Report. N Engl J Med. Jul 14:NEJMoa2022483 (2020). 32. N. B. Mercado, R. Zahn, F. Wegmann, C. Loos, A. Chandrashekar, J. Yu, J. Liu, L. Peter, K. McMahan, L. H. Tostanoski, X. He, D. R. Martinez, L. Rutten, R. Bos, D. van Manen, J. 37. B. Korber, W. M. Fischer, S. Gnanakaran, H. Yoon, J. Theiler, W. Abfalterer, N. Hengartner, [OpenAIRE]
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).13 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10% citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).13 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!
- Université Paris Diderot France
AbstractExtracellular vesicles (EVs) emerge as essential mediators of intercellular communication. DNA vaccines encoding antigens presented on EVs efficiently induce T-cell responses and EV-based vaccines containing the Spike (S) proteins of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) are highly immunogenic in mice. Thus, EVs may serve as vaccine platforms against emerging diseases, going beyond traditional strategies, with the antigen displayed identically to the original protein embedded in the viral membrane and presented as such to the immune system. Compared to their viral and pseudotyped counterparts, EV-based vaccines overcome many safety issues including pre-existing immunity against these vectors. Here, we applied our technology in natural EV’s engineering, to express the S proteins of SARS-CoV-2 embedded in the EVs, which mimic the virus with its fully native spikes. Immunizations with a two component CoVEVax vaccine, comprising DNA vector (DNAS-EV) primes, allowing in situ production of Spike harbouring EVs, and a boost using S-EVs produced in mammalian cells, trigger potent neutralizing and cellular responses in mice, in the absence of any adjuvants. CoVEVax would be the prototype of vaccines, where the sole exchange of the envelope proteins on EVs leads to the generation of new vaccine candidates against emerging viruses.